Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
July 27 2021 - 6:37AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the date of July 27, 2021
Commission File Number 001-39124
Centogene N.V.
(Translation of registrant's name into English)
Am Strande
7
18055 Rostock
Germany
(Address of principal executive offices)
Indicate by check mark whether the registrant files
or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F X Form
40-F ____
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate by check mark if the registrant is submitting
the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
Centogene N.V.
On July 27, 2021, Centogene N.V. issued a press release titled “CENTOGENE
Appoints Patrice P. Denèfle as Chief Scientific Officer to Lead Its Data-Driven Approach to Reinvent Rare Disease Drug Discovery
and Development”.
A copy of the press release is attached hereto as Exhibit 99.1.
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Date: July 27, 2021
|
CENTOGENE N.V.
|
|
|
|
|
|
By:
|
/s/ Rene Just
|
|
|
Name: Rene Just
|
|
|
Title: Chief Financial Officer
|
Exhibit Index
Exhibit
|
Description of Exhibit
|
99.1
|
Press release dated July 27, 2021
|
Centogene NV (NASDAQ:CNTG)
Historical Stock Chart
From Sep 2024 to Oct 2024
Centogene NV (NASDAQ:CNTG)
Historical Stock Chart
From Oct 2023 to Oct 2024